Janet M Siliciano

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/819281/publications.pdf Version: 2024-02-01



IANET M SULCIANO

#	Article	IF	CITATIONS
1	Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature Medicine, 1999, 5, 512-517.	30.7	1,962
2	Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine, 2003, 9, 727-728.	30.7	1,482
3	Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1 Cure. Cell, 2013, 155, 540-551.	28.9	1,207
4	Defective proviruses rapidly accumulate during acute HIV-1 infection. Nature Medicine, 2016, 22, 1043-1049.	30.7	605
5	Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies. PLoS Pathogens, 2013, 9, e1003174.	4.7	524
6	A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature, 2019, 566, 120-125.	27.8	471
7	Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature, 2015, 517, 381-385.	27.8	469
8	New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nature Medicine, 2014, 20, 425-429.	30.7	436
9	International AIDS Society global scientific strategy: towards an HIV cure 2016. Nature Medicine, 2016, 22, 839-850.	30.7	395
10	HIV-1 Integration Landscape during Latent and Active Infection. Cell, 2015, 160, 420-432.	28.9	393
11	Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 ⁺ T Cells. Journal of Virology, 2006, 80, 6441-6457.	3.4	377
12	Proliferation of latently infected CD4+ T cells carrying replication-competent HIV-1: Potential role in latent reservoir dynamics. Journal of Experimental Medicine, 2017, 214, 959-972.	8.5	327
13	Resting CD4 + T Cells from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals Carry Integrated HIV-1 Genomes within Actively Transcribed Host Genes. Journal of Virology, 2004, 78, 6122-6133.	3.4	306
14	Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature, 2020, 585, 261-267.	27.8	245
15	Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay. PLoS Pathogens, 2013, 9, e1003398.	4.7	228
16	Enhanced Culture Assay for Detection and Quantitation of Latently Infected, Resting CD4 ⁺ T-Cells Carrying Replication-Competent Virus in HIV-1-Infected Individuals. , 2005, 304, 003-016.		216
17	Orientation-Dependent Regulation of Integrated HIV-1 Expression by Host Gene Transcriptional Readthrough. Cell Host and Microbe, 2008, 4, 134-146.	11.0	190
18	HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. PLoS Medicine, 2017, 14, e1002417.	8.4	186

JANET M SILICIANO

#	Article	IF	CITATIONS
19	Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proceedings of the United States of America, 2018, 115, E2575-E2584.	7.1	173
20	Stability of the Latent Reservoir for HIVâ€l in Patients Receiving Valproic Acid. Journal of Infectious Diseases, 2007, 195, 833-836.	4.0	169
21	Transcriptional Reprogramming during Effector-to-Memory Transition Renders CD4+ T Cells Permissive for Latent HIV-1 Infection. Immunity, 2017, 47, 766-775.e3.	14.3	160
22	Differential decay of intact and defective proviral DNA in HIV-1–infected individuals on suppressive antiretroviral therapy. JCI Insight, 2020, 5, .	5.0	140
23	Characterization of Chemokine Receptor Utilization of Viruses in the Latent Reservoir for Human Immunodeficiency Virus Type 1. Journal of Virology, 2000, 74, 7824-7833.	3.4	139
24	Designing and Interpreting Limiting Dilution Assays: General Principles and Applications to the Latent Reservoir for Human Immunodeficiency Virus-1. Open Forum Infectious Diseases, 2015, 2, ofv123.	0.9	119
25	Antigen-driven clonal selection shapes the persistence of HIV-1–infected CD4+ T cells in vivo. Journal of Clinical Investigation, 2021, 131, .	8.2	103
26	Influence of Host Gene Transcription Level and Orientation on HIV-1 Latency in a Primary-Cell Model. Journal of Virology, 2011, 85, 5384-5393.	3.4	102
27	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
28	Measuring the Frequency of Latent HIV-1 in Resting CD4+ T Cells Using a Limiting Dilution Coculture Assay. Methods in Molecular Biology, 2016, 1354, 239-253.	0.9	92
29	Recent developments in the search for a cure for HIV-1 infection: Targeting the latent reservoir for HIV-1. Journal of Allergy and Clinical Immunology, 2014, 134, 12-19.	2.9	88
30	HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. Journal of Clinical Investigation, 2018, 128, 3102-3115.	8.2	88
31	CD4+ and CD8+ T Cell Activation Are Associated with HIV DNA in Resting CD4+ T Cells. PLoS ONE, 2014, 9, e110731.	2.5	88
32	Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 225-233.	4.0	80
33	Different human resting memory CD4 ⁺ T cell subsets show similar low inducibility of latent HIV-1 proviruses. Science Translational Medicine, 2020, 12, .	12.4	73
34	The Landscape of Persistent Viral Genomes in ART-Treated SIV, SHIV, and HIV-2 Infections. Cell Host and Microbe, 2019, 26, 73-85.e4.	11.0	71
35	Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation, 2020, 130, 3543-3559.	8.2	69
36	The Remarkable Stability of the Latent Reservoir for HIV-1 in Resting Memory CD4 ⁺ T Cells. Journal of Infectious Diseases, 2015, 212, 1345-1347.	4.0	68

JANET M SILICIANO

#	Article	IF	CITATIONS
37	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18692-18700.	7.1	67
38	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Science Translational Medicine, 2021, 13, .	12.4	54
39	A primary CD4+ T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescence. Nature Protocols, 2014, 9, 2755-2770.	12.0	46
40	Complex decay dynamics of HIV virions, intact and defective proviruses, and 2LTR circles following initiation of antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	46
41	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32066-32077.	7.1	44
42	The role of CD32 during HIV-1 infection. Nature, 2018, 561, E17-E19.	27.8	43
43	Recent trends in HIV-1 drug resistance. Current Opinion in Virology, 2013, 3, 487-494.	5.4	40
44	Engaging innate immunity in HIV-1 cure strategies. Nature Reviews Immunology, 2022, 22, 499-512.	22.7	39
45	Diverse fates of uracilated HIV-1 DNA during infection of myeloid lineage cells. ELife, 2016, 5, .	6.0	37
46	In Vivo Dynamics of the Latent Reservoir for HIV-1: New Insights and Implications for Cure. Annual Review of Pathology: Mechanisms of Disease, 2022, 17, 271-294.	22.4	37
47	A Possible Sterilizing Cure of HIV-1 Infection Without Stem Cell Transplantation. Annals of Internal Medicine, 2022, 175, 95-100.	3.9	36
48	Impact of Anti–PD-1 and Anti–CTLA-4 on the Human Immunodeficiency Virus (HIV) Reservoir in People Living With HIV With Cancer on Antiretroviral Therapy: The AIDS Malignancy Consortium 095 Study. Clinical Infectious Diseases, 2021, 73, e1973-e1981.	5.8	34
49	Assays to Measure Latency, Reservoirs, and Reactivation. Current Topics in Microbiology and Immunology, 2017, 417, 23-41.	1.1	31
50	Low Inducibility of Latent Human Immunodeficiency Virus Type 1 Proviruses as a Major Barrier to Cure. Journal of Infectious Diseases, 2021, 223, S13-S21.	4.0	29
51	HSF1 inhibition attenuates HIV-1 latency reversal mediated by several candidate LRAs In Vitro and Ex Vivo. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 15763-15771.	7.1	28
52	Finding a Cure for Human Immunodeficiency Virus-1 Infection. Infectious Disease Clinics of North America, 2014, 28, 633-650.	5.1	22
53	Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size. PLoS Computational Biology, 2019, 15, e1006849.	3.2	22
54	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. Clinical Infectious Diseases, 2017, 65, 1308-1315.	5.8	20

JANET M SILICIANO

#	Article	IF	CITATIONS
55	Insufficient Evidence for Rare Activation of Latent HIV in the Absence of Reservoir-Reducing Interventions. PLoS Pathogens, 2016, 12, e1005679.	4.7	19
56	Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size. Journal of Infectious Diseases, 2021, 224, 1209-1218.	4.0	18
57	Rekindled HIV infection. Science, 2014, 345, 1005-1006.	12.6	15
58	Nonsuppressible HIV-1 viremia: a reflection of how the reservoir persists. Journal of Clinical Investigation, 2020, 130, 5665-5667.	8.2	15
59	Similar Frequency and Inducibility of Intact Human Immunodeficiency Virus-1 Proviruses in Blood and Lymph Nodes. Journal of Infectious Diseases, 2020, 224, 258-268.	4.0	14
60	Biomarkers of HIV replication. Current Opinion in HIV and AIDS, 2010, 5, 491-497.	3.8	11
61	Allogeneic bone marrow transplantation with post-transplant cyclophosphamide for patients with HIV and haematological malignancies: a feasibility study. Lancet HIV,the, 2020, 7, e602-e610.	4.7	11
62	TCR-mimic bispecific antibodies to target the HIV-1 reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2123406119.	7.1	10
63	Nonstructured Treatment Interruptions Are Associated With Higher Human Immunodeficiency Virus Reservoir Size Measured by Intact Proviral DNA Assay in People Who Inject Drugs. Journal of Infectious Diseases, 2021, 223, 1905-1913.	4.0	8
64	Efforts to eliminate the latent reservoir in resting CD4+ T cells: strategies for curing HIV-1 infection. Journal of Virus Eradication, 2015, 1, 229-31.	0.5	4
65	Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques. Npj Vaccines, 2022, 7, 53.	6.0	4
66	108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, S183-S183.	0.9	1
67	Reply. Journal of Allergy and Clinical Immunology, 2015, 136, 214.	2.9	0